Cognition Therapeutics CEO Issues Letter to Shareholders

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803877/0/en/Cognition-Therapeutics-CEO-Issues-Letter-to-Shareholders.html

Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer’s disease anticipated in mid 2024

Topline data from Phase 2 SHIMMER trial in mild-to-moderate dementia with Lewy bodies anticipated in the second half of 2024

Read more at globenewswire.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.